Pulsed estrogen exposure selectively modulates tissue response: A hypothesis

Gynecological Endocrinology

Volumn 18, Issue 3, 2004, Pages 159-164

  Kenemans, P ^a   Genazzani, A R ^b   Palacios, S ^c   Schneider, H P G ^d  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF PISA   (Italy)

^c Instituto Palacios de Salud Y Medicina de la Mujer   (Spain)

^d UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

2 Methoxyestradiol; Estradiol kinetic; Estrogen receptors; Pulsed estrogen therapy; Tissue selectivity

Indexed keywords

2 METHOXYESTRADIOL; DRUG METABOLITE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA;

ANTINEOPLASTIC ACTIVITY; BLEEDING; BONE; BREAST; CLINICAL TRIAL; DRUG EFFECT; DRUG EXPOSURE; DRUG MECHANISM; DRUG SELECTIVITY; DRUG SPECIFICITY; ENDOMETRIUM; ESTROGEN BLOOD LEVEL; ESTROGEN THERAPY; GENOMICS; HEMOCONCENTRATION; HORMONE SUBSTITUTION; HUMAN; HYPOTHESIS; KINETICS; MASTALGIA; MENOPAUSAL SYNDROME; OSTEOLYSIS; OVARY FOLLICLE; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RECEPTOR UPREGULATION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; STIMULATION; TIME; TISSUE METABOLISM; TISSUE REACTION; UTERUS;

ADMINISTRATION, INTRANASAL; ANIMALS; BREAST; ENDOMETRIUM; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; KINETICS; MODELS, BIOLOGICAL; PERIODICITY; POSTMENOPAUSE; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION;

EID: 1542327586     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.1080/09513590310001653035     Document Type: Review

References (30)

1. Devissaguet JP, Brion N, Lhote O, et al. Pulsed estrogen therapy: pharmacokinetics of intranasal 17-beta-estradiol (S21400) in postmenopausal women and comparison with oral and transdermal formulations. Eur J Drug Metab Pharmacokinet 1999;24:265-71
2. Studd J, Pornel B, Marton I, et al. Efficacy and acceptability of intranasal 17 beta-oestradiol for menopausal symptoms: randomised dose-response study. Aerodiol Study Group. Lancet 1999;353:1574-8
3. Lopes P, Merkus HM, Nauman J, et al. Randomized comparison of intranasal and transdermal estradiol. Obstet Gynecol 2000;96:906-12
4. Palacios S, Rodowicki S, Marton I, et al. Pulsed estrogen therapy prevents late postmenopausal bone loss: a 2 year placebo-controlled study. Maturitas 2003;44(Suppl. 2):FC04,7
5. Pitkin J, Chetaille E, Bagger Y, et al. Improvement of postmenopausal quality of life after pulsed estrogen therapy: a 2 year placebo-controlled study. Maturitas 2003;44(Suppl. 2):FC06,7
6. Kerdelhue B, Jolette J. The influence of the route of administration of 17beta-estradiol, intravenous (pulsed) versus oral, upon DMBA-induced mammary tumour development in ovariectomised rats. Breast Cancer Res Treat 2002;73:13-22
7. Simoncini T, Genazzani AR. Non-genomic actions of sex steroid hormones. Eur J Endocrinol 2003;148:281-92
8. Cavailles V, Gompel A, Portois MC, et al. Comparative activity of pulsed or continuous estradiol exposure on gene expression and proliferation of normal and tumoral human breast cells. J Mol Endocrinol 2002;28:165-75
9. Simoncini T, Manella P, Fornari L, et al. Genomic and non-genomic vascular regulation of nitric oxide by pulsed estradiol administration. Climacteric 2002;5(Suppl. 2): F-15-07
10. Kenemans P. Tissue specificity of sex hormones and so-called modulation of receptors and enzymes. Maturitas 2001;37:145-6
11. Nilsson S, Gustafsson JA. Estrogen receptor transcription and transactivation: basic aspects of estrogen action. Breast Cancer Res 2000;2:360-6
12. Roger P, Sahla ME, Makela S, et al. Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res 2001;61:2537-41
13. Forster C, Makela S, Warri A, et al. Involvement of estrogen receptor beta in terminal differentiation of mammary gland epithelium. Proc Natl Acad Sci USA 2002;99:15578-83
14. Konstantinopoulos PA, Kominea A, Vandoros G, et al. Oestrogen receptor beta (ERbeta) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour's dedifferentiation. Eur J Cancer 2003;39:1251-8
15. Weihua Z, Saji S, Makinen S, et al. Estrogen receptor (ER) beta, a modulator of ERalpha in the uterus. Proc Natl Acad Sci USA 2000;97:5936-41
16. Wang H, Isaksson E, Von Schoultz B, et al. The effect of long-term treatment with steroid hormones or tamoxifen on oestrogen receptors (alpha and beta) in the endometrium of ovariectomized cynomolgus macaques. J Endocrinol 2002;175:673-81
17. Rosser M, Chorich L, Howard E, et al. Changes in rat uterine estrogen receptor messenger ribonucleic acid levels during estrogen- and progesterone-induced estrogen receptor depletion and subsequent replenishment. Biol Reprod 1993;48:89-98
18. Ihionkhan CE, Chambliss KL, Gibson LL, et al. Estrogen causes dynamic alterations in endothelial estrogen receptor expression. Circ Res 2002;91:814-20
19. Buteau-Lozano H, Ancelin M, Lardeux B, et al. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta. Cancer Res 2002;62:4977-84
20. Mitchner NA, Garlick C, Ben Jonathan N. Cellular distribution and gene regulation of estrogen receptors alpha and beta in the rat pituitary gland. Endocrinology 1998;139:3976-83
21. Lindberg MK, Alatalo SL, Halleen JM, et al. Estrogen receptor specificity in the regulation of the skeleton in female mice. J Endocrinol 2001;171:229-36
22. Hall JM, McDonnell DP. The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 1999;140:5566-78
23. Riggs BL, Hartmann LC. Selective estrogen-receptor modulators - mechanisms of action and application to clinical practice. N Engl J Med 2003;348:618-29
24. McKenna NJ, O'Malley BW. Minireview: nuclear receptor coactivators - an update. Endocrinology 2002;143:2461-5
25. Zhu BT. Catechol-o-methyltransferase (COMT)-mediated methylation metabolism of endogenous bioactive catechols and modulation by endobiotics and xenobiotics: importance in pathophysiology and pathogenesis. Curr Drug Metab 2002;3:321-49
26. Lakhani NJ, Sarkar MA, Venitz J, et al. 2-Methoxyestradiol, a promising anticancer agent. Pharmacotherapy 2003;23:165-72
27. Shang W, Konidari I, Schomberg DW. 2-Methoxyestradiol, an endogenous estradiol metabolite, differentially inhibits granulosa and endothelial cell mitosis: a potential follicular antiangiogenic regulator. Biol Reprod 2001;65:622-7
28. Dubey RK, Gillespie DG, Zacharia LC, et al. CYP450- and COMT-denrived estradiol metabolites inhibit activity of human coronary artery SMCs. Hypertension 2003;41:807-13
29. Zhu BT. Medical hypothesis: Hyperhomocysteinemia is a risk factor for estrogen-induced hormonal cancer. Int J Oncol 2003;22:499-508
30. Tsutsui Y, Tamura Y, Yagi E, et al. Involvement of genotoxic effects in the initiation of estrogen-induced cellular transformation: studies using Syrian hamster embryo cells treated with 17beta-estradiol and eight of its metabolites. Int J Cancer 2000;86:8-14